[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638559":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":45,"collaborators":18,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":18,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":74,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lidocaine Group","EXPERIMENTAL","Participants in this group will receive perioperative intravenous lidocaine infusion according to ideal body weight. A loading dose of 1.5 mg\u002Fkg lidocaine diluted in 50 or 100 mL normal saline will be administered over 10 minutes before surgery, followed by an infusion of 1.5 mg\u002Fkg\u002Fhour during surgery. If the operation exceeds 2 hours, the infusion will be discontinued. The duration of surgery will be recorded. Lidocaine infusion will be stopped immediately if signs suggestive of local anesthetic systemic toxicity or unexplained hemodynamic instability occur during surgery.",[13],"Drug: Lidocaine",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Group","NO_INTERVENTION","Participants in this group will receive standard perioperative care without intravenous lidocaine infusion during elective laparoscopic TAPP inguinal hernia repair.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Lidocaine","Perioperative intravenous lidocaine infusion will be administered according to the study protocol in patients undergoing elective laparoscopic TAPP inguinal hernia repair.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Hakan Emirkadı, MD","CONTACT","+905322609367","hemirkadi@gmail.com",[32],{"facility":33,"status":18,"city":34,"state":34,"zip":35,"country":36,"countryCode":18,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"University of Health Sciences Sultan Abdulhamid Han Training and Research Hospital","Istanbul","34668","Turkey (Türkiye)",{"type":38,"coordinates":39},"Point",[40,41],28.94966,41.01384,{"lat":41,"lon":40},[44],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"SPONSOR_INVESTIGATOR","Hakan Emirkadı","Anesthesiology and Reanimation Specialist","100638559","intravenous-lidocaine-for-postoperative-fatigue-after-laparoscopic-tapp-inguinal-hernia-repair-100638559",false,"NCT07612839","Intravenous Lidocaine for Postoperative Fatigue After Laparoscopic TAPP Inguinal Hernia Repair","The Effect of Intravenous Lidocaine on Postoperative Fatigue Syndrome in Patients Undergoing Elective Laparoscopic TAPP Inguinal Hernia Repair","LIDO-TAPP","Inclusion Criteria:\n\nAdult patients aged 18 years and older Patients scheduled for elective laparoscopic TAPP inguinal hernia repair under general anesthesia ASA physical status I-II Patients who provide written informed consent -\n\nExclusion Criteria:\n\nModerate to severe hepatic dysfunction Low cardiac output or severe heart failure Severe cardiac conduction abnormalities or clinically significant arrhythmias Planned concomitant use of high-dose local anesthetics, including infiltration or regional block Advanced age or frailty Pregnancy or breastfeeding Known allergy or contraindication to lidocaine Refusal to participate in the study\n\n\\-","ALL","18 Years",{"count":60,"type":61},80,"ESTIMATED","INTERVENTIONAL",[64],"NA","This prospective randomized controlled study aims to evaluate the effect of perioperative intravenous lidocaine infusion on postoperative fatigue syndrome in patients undergoing elective laparoscopic TAPP inguinal hernia repair. Participants will be randomly assigned to receive either intravenous lidocaine infusion or standard perioperative management without lidocaine. The primary objective is to assess postoperative fatigue and recovery quality. Secondary outcomes include postoperative pain, analgesic consumption, nausea-vomiting, mobilization time, and length of hospital stay.",[67,68],"Postoperative Fatigue Syndrome","Inguinal Hernia Unilateral",[70,71,72,73],"Intravenous Lidocaine","Postoperative Fatigue","Laparoscopic TAPP Repair","Postoperative Recovery","NOT_YET_RECRUITING","2026-05-21",{"date":77,"type":78},"2026-05-29","ACTUAL",{"date":80,"type":61},"2026-06-05",{"date":82,"type":61},"2026-09-10",{"name":47,"class":6},1]